Phase II neoadjuvant pyrotinib combined with epirubicin and cyclophosphamide followed by docetaxel in HER2-low-expressing and HR-positive early or locally advanced breast cancer (PILHLE-001): A single-arm trial.

被引：0
|
作者：
Xia, Yuan
Yang, Wenqian
Yang, Ya-Ping
Zhu, Yingying
Zeng, Yinduo
Qin, Tao
Jia, Shijie
Chen, Jiayi
Gong, Chang
机构：
[1] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Clin Res Design Div, Clin Res Ctr, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Oncol, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS620
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PILHLE-001: neoadjuvant pyrotinib combined with chemotherapy in HR-positive, HER2-low (IHC 2+/FISH-negative) early breast cancer
    Gong, Chang
    Xia, Yuan
    Zhu, Yingying
    Yang, Yaping
    Yang, Wenqian
    Chow, Louis W. C.
    Ling, Li
    Zeng, Yunjie
    Zhong, Jiajie
    Cheng, Ziliang
    Shen, Jun
    Lin, Qun
    Zeng, Yinduo
    Liu, Qiang
    Song, Erwei
    CANCER RESEARCH, 2024, 84 (09)
  • [2] Epirubicin, cyclophosphamide and pyrotinib followed by docetaxel, trastuzumab and pyrotinib as neoadjuvant therapy for stage II-III HER2-positive breast cancer: a single-arm, multicenter phase 2 trial
    Shi, Qiyun
    Qi, Xiaowei
    Tang, Peng
    Fan, Linjun
    Chen, Li
    Wang, Shushu
    Zhang, Guozhi
    Wang, Mengyuan
    Che, Hongying
    Lv, Pengwei
    Chen, Dejie
    Hu, Jinhui
    Li, Qiuyun
    Zhang, Yanwu
    Yu, Qiao
    Yang, Kunxian
    Zhong, Yuan
    Chen, Chuang
    Zhou, Zemin
    Qian, Liyuan
    Zhang, Jingwei
    Ma, Mingde
    Sun, Yi
    Liu, Jiangbo
    Zhang, Yi
    Jiang, Jun
    CANCER RESEARCH, 2023, 83 (05)
  • [3] Preclinical study and phase 2 trial of neoadjuvant pyrotinib combined with chemotherapy in luminal/HER2-low breast cancer: PILHLE-001 study
    Gong, Chang
    Xia, Yuan
    Zhu, Yingying
    Yang, Yaping
    Lin, Qun
    Liu, Qiang
    Yang, Wenqian
    Ling, Li
    Zhong, Jiajie
    Duan, Zhuxi
    Zeng, Yunjie
    Cheng, Ziliang
    Shen, Jun
    Zeng, Yinduo
    Chow, Louis Wing Cheong
    Song, Erwei
    CELL REPORTS MEDICINE, 2024, 5 (11)
  • [4] Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial
    Min Yan
    Limin Niu
    Huimin Lv
    Mengwei Zhang
    Jing Wang
    Zhenzhen Liu
    Xiuchun Chen
    Zhenduo Lu
    Chongjian Zhang
    Huiai Zeng
    Shengnan Zhao
    Yajing Feng
    Huihui Sun
    Huajun Li
    Nature Communications, 14
  • [5] Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial
    Yan, Min
    Niu, Limin
    Lv, Huimin
    Zhang, Mengwei
    Wang, Jing
    Liu, Zhenzhen
    Chen, Xiuchun
    Lu, Zhenduo
    Zhang, Chongjian
    Zeng, Huiai
    Zhao, Shengnan
    Feng, Yajing
    Sun, Huihui
    Li, Huajun
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [6] Phase II study of combined docetaxel, epirubicin, and cyclophosphamide as a neoadjuvant chemotherapy regimen in patients with locally advanced breast cancer in a single institution
    Yao, X.
    Hosenpud, J. R.
    Chitambar, C. R.
    Charlson, J. A.
    Cheng, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Efficacy and safety of pyrotinib combined with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer (BC): A single-arm phase II trial.
    Hao, Chunfang
    Qi, Xiaowei
    Shi, Yehui
    Tong, Zhongsheng
    Zhang, Jie
    Meng, Wenjing
    Yang, Xiaonan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Combined pyrotinib and fulvestrant for hormone receptor-positive and HER2-positive metastatic breast cancer: A multicenter, single-arm, phase II trial
    Zhao, Jianli
    Yu, Yunfang
    Ren, Wei
    Ding, Linxiaoxiao
    Chen, Yongjian
    Yuan, Peng
    Yue, Jian
    Yang, Yaping
    Zou, Guorong
    Chen, Tao
    Chai, Jie
    Zhang, Li
    Wu, Wenjing
    Zeng, Yinduo
    Gui, Xiujuan
    Cai, Yangyang
    Luo, Simin
    Yuan, Zhongyu
    Zhang, Kang
    Yao, Herui
    Wang, Ying
    MEDCOMM, 2025, 6 (01):
  • [9] Short-term efficacy and safety of neoadjuvant pyrotinib plus taxanes for early HER2-positive breast cancer: a single-arm exploratory phase II trial
    Ye, Guolin
    Chen, Peixian
    Liu, Xiangwei
    He, Tiancheng
    Pivot, Xavier
    Pan, Ruilin
    Zhou, Dan
    Zhu, Lewei
    Zhang, Kun
    Li, Wei
    Yang, Shuqing
    Lin, Jiawei
    Cai, Gengxi
    Huang, Huiqi
    GLAND SURGERY, 2024, 13 (03) : 374 - 382
  • [10] Inetetamab combined with pyrotinib and oral vinorelbine for patients with HER2-positive metastatic breast cancer: a single-arm phase 2 trial
    Huang, Xiang
    Jin, Nan
    Sun, Chunxiao
    Yan, Xueqi
    Yang, Fan
    Liang, Yan
    Li, Wei
    Yin, Yongmei
    CANCER RESEARCH, 2024, 84 (09)
12345